Clinical Trial Update: A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a VEGF-Antisense Oligonucleotide in combination with pemetrexed and cisplatin for advanced malignant mesothelioma has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• VEGF-Antisense Oligonucleotide

Snippet

Sponsor: University of Southern California | Conditions: Mesothelioma | Phase 1, Phase 2 | Status: WITHDRAWN